Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation

Danielle Brazel; Shannon Zhang; Misako Nagasaka

doi:10.2147/LCTT.S360574

Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation

Lung Cancer (Auckl). 2022 May 13:13:33-45. doi: 10.2147/LCTT.S360574. eCollection 2022.

Authors

Danielle Brazel¹, Shannon Zhang¹, Misako Nagasaka^{1

2

3}

Affiliations

¹ Department of Medicine, University of California Irvine School of Medicine, Orange, CA, USA.
² Chao Family Comprehensive Cancer Center, Orange, CA, USA.
³ Department of Medicine, St. Marianna University School of Medicine, Kawasaki, Japan.

Abstract

Mesenchymal-epithelial transition (MET) receptor tyrosine kinase is overexpressed, amplified, or mutated in 1-20% of NSCLC. MET dysregulation is associated with a poor prognosis. Recently, development of targeted therapies against MET exon 14 mutations has demonstrated efficacy and tolerability in early trials. Here we focus on tepotinib and capmatinib in regards to molecular characteristics, early preclinical and clinical data, and the emerging role in future studies and clinical practice.

Keywords: MET; RET; capmatinib; mesenchymal-epithelial transition inhibitors; non-small cell lung cancer; tepotinib.

Grants and funding

No funding was secured for this report.